title: Teniposide (VM-26) and cytosine arabinoside as consolidation therapy in adult high-risk patients with acute lymphoblastic leukemia.
authors.forename: D
authors.initials: D
authors.lastname: Hoelzer
authors.forename: E
authors.initials: E
authors.lastname: Thiel
authors.forename: H
authors.initials: H
authors.lastname: Löffler
authors.forename: T
authors.initials: T
authors.lastname: Büchner
authors.forename: A
authors.initials: A
authors.lastname: Ganser
authors.forename: G
authors.initials: G
authors.lastname: Heil
authors.forename: E
authors.initials: E
authors.lastname: Kurrle
authors.forename: H
authors.initials: H
authors.lastname: Heimpel
authors.forename: P
authors.initials: P
authors.lastname: Koch
authors.forename: T
authors.initials: T
authors.lastname: Lipp
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage*; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008875:Middle Aged; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011379:Prognosis; D013713:Teniposide / Q000008:administration & dosage*
chemical_list: D003561:Cytarabine; D013713:Teniposide; D011034:Podophyllotoxin